Cortistatin, a new antiinflammatory peptide with therapeutic effect on lethal endotoxemia

Journal of Experimental Medicine

Volumn 203, Issue 3, 2006, Pages 563-571

  Gonzalez Rey, Elena ^a   Chorny, Alejo ^a   Robledo, Gema ^a   Delgado, Mario ^a  

^a INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; ANTIINFLAMMATORY AGENT; CHEMOKINE; CORTISTATIN; CYTOKINE; ESCHERICHIA COLI ENDOTOXIN; IMMUNOMODULATING AGENT; OCTREOTIDE; PEPTIDE; SOMATOSTATIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISSEMINATED INTRAVASCULAR CLOTTING; DOWN REGULATION; DRUG EFFECT; ENDOTOXEMIA; ESCHERICHIA COLI; EXPERIMENTAL INFECTION; HISTOPATHOLOGY; IMMUNOMODULATION; INFLAMMATORY INFILTRATE; LARGE INTESTINE PERFORATION; LETHALITY; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEPTIC SHOCK;

ANIMALS; CYTOKINES; DISSEMINATED INTRAVASCULAR COAGULATION; ENDOTOXEMIA; ENDOTOXINS; HUMANS; INFLAMMATION; INJECTIONS, INTRAPERITONEAL; MICE; MICE, INBRED BALB C; NEUROPEPTIDES; PEPTIDES, CYCLIC;

EID: 33645080443     PISSN: 00221007     EISSN: 00221007     Source Type: Journal    
DOI: 10.1084/jem.20052017     Document Type: Article

References (32)

1. Danner, R.L., R.J. Elin, J.M. Hosseini, R.A. Wesley, J.M. Reilly, and J.E. Parillo. 1991. Endotoxemia in human septic shock. Chest. 99: 169-175.
2. Netea, M.G., J.W. van der Meer, M. van Deuren, and B.J. Kullberg. 2003. Proinflammatory cytokines and sepsis syndrome: not enough, or too much of a good thing? Trends Immunol. 24:254-258.
3. Bochud, P.Y., and T. Calandra. 2003. Pathogenesis of sepsis: new concepts and implications for future treatment. BMJ. 326:262-266.
4. Sessler, C.N., and W. Shepherd. 2002. New concepts in sepsis. Curr. Opin. Crit. Care. 8:465-472.
5. de Lecea, L., J.R. Criado, O. Prospero-Garcia, K.M. Gautvik, P. Schweitzer, P.E. Danielson, C.L. Dunlop, G.R. Siggins, S.J. Henriksen, and J.G. Sutcliffe. 1996. A cortical neuropeptide with neuronal depressant and sleep-modulating properties. Nature. 381:242-245.
6. Spier, A.D., and L. de Lecea. 2000. Cortistatin: a member of the somatostatin neuropeptide family with distinct physiological functions. Brain Res. Brain Res. Rev. 33:228-241.
7. Dalml, V.A., P.M. van Hagen, P.M. van Koetsveld, S. Achilefu, A.B. Houtsmuller, D.H. Pols, A.J. van der Lely, S.W. Lamberts, and L.J. Hofland. 2003. Expression of somatostatin, cortistatin, and somatostatin receptors in human monocytes, macrophages, and dendritic cells. Am. J. Physiol. Endocrinol. Metab. 285:E344-E353.
8. Dalm, V.A. 2003. Cortistatin rather than somatostatin as a potential endogenous ligand for somatostatin receptors in the human immune system. J. Clin. Endocrinol. Metab. 88:270-276.
9. Krantic, S. 2000. Peptides as regulators of the immune system: emphasis on somatostatin. Peptides. 21:1941-1964.
10. Deghenghi, R., M. Papotti, E. Ghigo, and G. Muccioli. 2001. Cortistatin, but not somatostatin, binds to growth hormone secretagogue (GHS) receptors of human pituitary gland. J. Endocrinol. Invest. 24:RC1-RC3.
11. Dixit, V.D., E.M. Schaffer, R.S. Pyle, G.D. Collins, S.K. Sakthivel, R. Palaniappan, J.W. Lillard Jr., and D.D. Taub. 2004. Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells. J. Clin. Invest. 114:57-66.
12. Granado, M., T. Priego, A.I. Martin, M.A. Villanua, and A. Lopez-Calderon. 2005. Anti-inflammatory effect of the ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2) in arthritic rats. Am. J. Physiol. Endocrinol. Metab. 288:E486-E492.
13. Howard, M., T. Muchamuel, S. Andrade, and S. Menon. 1993. Interleukin 10 protects mice from lethal endotoxemia. J. Exp. Med. 177:1205-1208.
14. Dhainaut, J., N. Marin, A. Mignon, and C. Vinsonneau. 2001. Hepatic response to sepsis: interaction between coagulation and inflammatory processes. Crit. Care Med. 29:S42-S47.
15. Delgado, M., C. Martinez, D. Pozo, J.R. Calvo, J. Leceta, D. Ganea, and R.P. Gomariz. 1999. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNFα and IL- 6. J. Immunol. 162:1200-1205.
16. Delgado, M., D. Pozo, and D. Ganea. 2004. The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol. Rev. 56:249-290.
17. Zeni, F., B. Freeman, and C. Natanson. 1997. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit. Care Med. 25:1095-1100.
18. Tracey, K.J., B. Beutler, S.F. Lowry, J. Merryweather, S. Wolpe, I.W. Milsark, R.J. Hariri, T.J. Fahey 3rd, A. Zentella, and J.D. Albert. 1986. Shock and tissue injury induced by recombinant human cachectin. Science. 234:470-473.
19. Tracey, K.J., and A. Cerami. 1993. Tumor necrosis factor, other cytokines and disease. Annu. Rev. Cell Biol. 9:317-343.
20. Starnes, H.F., M.K. Pearce, A. Tewari, J.H. Yim, J.C. Zou, and J.S. Abrams. 1990. Anti-IL-6 monoclonal antibodies protect against lethal E. coli infection and lethal tumor necrosis factor-α challenge in mice. J. Immunol. 145:4185-4191.
21. Doherty, G.M., J.R. Lange, H.N. Langstein, H.R. Alexander, C.M. Buresh, and J.A. Norton. 1992. Evidence for IFN-γ as a mediator of the lethality of endotoxin and tumor necrosis factor-α. J. Immunol. 149:1666-1670.
22. Solorzano, C.C., R. Ksontini, J.H. Pruitt, T. Auffenberg, C. Tannahill, R.E. Galardy, G.P. Schultz, S.L. MacKay, E.M. Copeland 3rd, and L.L. Moldawer. 1997. A matrix metalloproteinase inhibitor prevents processing of tumor necrosis factor α and abrogates endotoxin-induced lethality. Shock. 7:427-431.
23. Liaw, Y.S., C.J. Yu, H.D. Wu, and P.C. Yang. 1997. Comparison of inflammatory cytokine concentration and physiologic parameters in septic shock. J. Formos. Med. Assoc. 96:685-690.
24. Tracey, K.J., Y. Fong, D.G. Hesse, K.R. Manogue, A.T. Lee, G.C. Kuo, S.F. Lowry, and A. Cerami. 1987. Anti-cachectin rTNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 330:662-664.
25. Heinzel, F.P., R.M. Rerko, P. Ling, J. Hakimi, and D.S. Schoenhaut. 1994. Interleukin 12 is produced in vivo during endotoxemia and stimulates synthesis of gamma interferon. Infect. Immun. 62:4244-4249.
26. Netea, M.G., G. Fantuzzi, B.J. Kullberg, R.J. Stuyt, E.J. Pulido, R.C. McIntyre Jr., L.A. Joosten, J.W. Van der Meer, and C.A. Dinarello. 2000. Neutralization of IL-18 reduces neutrophil tissue accumulation and protect mice against lethal Escherichia coli and Salmonella typhimurium endotoxemia. J. Immunol. 264:2644-2649.
27. Ramirez, J.L., R. Mouchantaf, U. Kumar, V. Otero Corchon, M. Rubinstein, M.J. Low, and Y.C. Patel. 2002. Brain somatostatin receptors are up-regulated in somatostatin-deficient mice. Mol. Endocrinol. 16:1951-1963.
28. Baxter, J.N., S.A. Jenkins, D.W. Day, N.B. Roberts, D.C. Cowell, C.R. Mackie, and R. Shields. 1985. Effects of somatostatin and a long-acting somatostatin analogue on the prevention and treatment of experimentally induced acute pancreatitis in the rat. Br. J. Surg. 72:382-385.
29. Landa, I., J. Arias, M. Gomez, M. Quadros, A. Moreno, and J.L. Balibrea. 1992. Cytoprotective effect of somatostatin in a rat model of hepatic ischemic reperfusion. Hepatology. 16:1474-1476.
30. Ogden, B.E., M.A. Martin Jr., A.S. Hall, E.A. Woltering, and R.E. Bryant. 1994. Octreotide does not alter endotoxin lethality in mice or endotoxin-induced suppression of human leukocyte migration. Life Sci. 55:PL277-PL285.
31. Gonzalez-Rey, E., A. Chorny, and M. Delgado. 2006. Therapeutic action of ghrelin in a murine model of colitis. Gastroenterology. In press.
32. Bradley, P.P., D.A. Priebat, R.D. Christensen, and G. Rothstein. 1982. Cellular and extracellular myeloperoxidase in pyogenic inflammation. J. Invest. Dermatol. 78:206-209.